Leukoregulin Induction of Prostaglandin-endoperoxide H Synthase-2 in Human Orbital Fibroblasts. An in Vitro Model for Connective Tissue Inflammation
Overview
Affiliations
Several proinflammatory cytokines can increase prostaglandin E2 (PGE2) synthesis in a variety of cell types, constituting an important component of the inflammatory response. We demonstrate here that leukoregulin, a 50-kDa product of activated T lymphocytes, dramatically increases PGE2 synthesis in cultured human orbital fibroblasts. This up-regulation is mediated through an induction of prostaglandin-endoperoxide H synthase-2 (PGHS-2), the inflammatory cyclooxygenase. Steady-state levels of PGHS-2 mRNA are increased within 1.5 h of leukoregulin addition and are near maximal by 6 h, when they are 50-fold or higher above basal levels. The increase in PGHS-2 mRNA levels is partially blocked by cycloheximide, suggesting de novo synthesis of an intermediate protein may be required for a maximal leukoregulin response. Nuclear run-on studies indicate PGHS-2 gene transcription is up-regulated by leukoregulin 2-fold after 2 and 6 h. PGHS-2 protein, as assessed by Western blotting and two-dimensional protein gel analysis, is increased dramatically in orbital fibroblasts. This lymphokine-dependent expression of PGHS-2 is blocked by dexamethasone, and the increase in PGE2 and cAMP levels following leukoregulin treatment is also blocked by indomethacin and by SC 58125, a newly developed PGHS-2-selective cyclooxygenase inhibitor. The dramatic increase in cAMP levels causes marked alteration in orbital fibroblast morphology. PGHS-2 expression in dermal fibroblasts is also increased by leukoregulin; however, the response is considerably less robust, and these cells do not undergo a change in morphology. Both orbital and dermal fibroblasts express high levels of PGHS-1 mRNA and protein, the other abundant form of cyclooxygenase. In contrast to its effects on PGHS-2 expression, leukoregulin fails to alter PGHS-1 levels in either orbital or dermal fibroblasts, suggesting that PGHS-1 is not involved in cytokine-dependent prostanoid production in human fibroblasts. The increased PGHS-2 expression elicited by leukoregulin in orbital fibroblasts may be a consequence of both transcriptional and post-transcriptional effects. These observations help clarify the pathogenic mechanism relevant to the intense inflammation associated with Graves' ophthalmopathy. Lymphocytes trafficked to orbital tissues have a putative role, through the cytokines they release, in the activation of fibroblasts in this autoimmune disease.
The changing landscape of thyroid eye disease: current clinical advances and future outlook.
Moledina M, Damato E, Lee V Eye (Lond). 2024; 38(8):1425-1437.
PMID: 38374366 PMC: 11126416. DOI: 10.1038/s41433-024-02967-9.
Understanding Pathogenesis Intersects With Effective Treatment for Thyroid Eye Disease.
Smith T J Clin Endocrinol Metab. 2022; 107(Suppl_1):S13-S26.
PMID: 36346686 PMC: 9359447. DOI: 10.1210/clinem/dgac328.
Influence of Cytokines on Inflammatory Eye Diseases: A Citation Network Study.
Galvez B, Martinez-Perez C, Villa-Collar C, Alvarez-Peregrina C, Sanchez-Tena M J Clin Med. 2022; 11(3).
PMID: 35160111 PMC: 8836545. DOI: 10.3390/jcm11030661.
2021 update on thyroid-associated ophthalmopathy.
Neag E, Smith T J Endocrinol Invest. 2021; 45(2):235-259.
PMID: 34417736 PMC: 9455782. DOI: 10.1007/s40618-021-01663-9.
Teprotumumab as a Novel Therapy for Thyroid-Associated Ophthalmopathy.
Smith T Front Endocrinol (Lausanne). 2021; 11:610337.
PMID: 33391187 PMC: 7774640. DOI: 10.3389/fendo.2020.610337.